Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tocilizumab in systemic juvenile idiopathic arthritis (sJIA)
jRCT2080220017Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on jRCT2080220017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220017.